Data from PALOMA-3 for Subcutaneous Amivantamab in EGFR-Mutated NSCLC

Narjust Florez, MD, summarizes clinical data from the phase 3 PALOMA-3 study (NCT05388669) evaluating a amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; subcutaneous amivantamab) in EGFR-mutated non–small cell lung cancer (NSCLC). Florez highlights pharmacokinetic comparability, administration time, and safety findings relative to the intravenous formulation of amivantamab. She contextualizes these data within the broader treatment landscape, focusing on potential implications for infusion-related reactions and overall treatment delivery.